Pfizer Inc.
PFEHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframePfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. Valued at $149.21B, PFE is a large-cap name in its sector. It operates in three segments: Biopharma, PC1, and Pfizer Ignite.
Market Cap
$149.21B
Beta
0.30
P/E (TTM)
19.98
P/E (Fwd)
9.23
EPS (TTM)
$1.31
EPS (Fwd)
$2.84
ROE
8.3%
ROA
5.7%
Cash
$13.08B
Total Debt
$64.73B
Free CF
$12.38B
52W Change
11.6%
Annual Financials
Cash vs Debt
Pfizer Inc. carries $64.73B in total debt against $13.08B in cash reserves — debt is roughly 4.9x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $12.38B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 8.3%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has pulled back from $101.17B (2022) to $62.58B (2025), a 38% decline worth watching.
With a beta below 0.7, Pfizer Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Pfizer Inc.'s trajectory.